November Meeting - Appendix

Table 1: Patient characteristics of Cohort 2

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Whole Sample | No LRA | Statins | Bile acid sequestrants | Ezetimibe | Ezetimibe & Statins | Fibrates | Nicotinic acid groups | Omega-3 Fatty Acid Groups |
| N | 1711679 | 1118835 | 581607 | 5353 | 754 | 126 | 3851 | 164 | 989 |
| Median year of prescription | 2006 | 2007 | 2004 | 2005 | 2004 | 2005 | 2001 | 2001 | 2005 |
| Female | 53.1% (908485) | 56.1% (627885) | 47.2% (274465) | 66.6% (3563) | 54.4% (410) | 53.2% (67) | 38.6% (1486) | 54.9% (90) | 52.5% (519) |
| Age | 57 | 54 | 62 | 57 | 60 | 57 | 58 | 62 | 56 |
| CAD | 0.4% (6958) | 0.1% (640) | 1.1% (6240) | 0.1% (6) | 0.9% (7) | 0.0% (0) | 1.4% (52) | 0.0% (0) | 1.3% (13) |
| CBS | 0.3% (5637) | 0.1% (737) | 0.8% (4811) | 0.1% (4) | 0.3% (2) | 0.0% (0) | 2.0% (77) | 0.0% (0) | 0.6% (6) |
| CVD | 2.1% (35221) | 1.1% (12271) | 3.9% (22648) | 1.6% (87) | 2.5% (19) | 2.4% (3) | 4.4% (169) | 4.3% (7) | 1.7% (17) |
| Charlson | 30.5% (522861) | 25.3% (283262) | 40.3% (234585) | 42.2% (2259) | 41.2% (311) | 24.6% (31) | 50.5% (1945) | 43.3% (71) | 40.1% (397) |
| IMD-2010 | 9 | 8 | 9 | 8 | 9 | 13 | 10 | 10 | 9.5 |
| Consulation rate | 5.4 (5.4) | 5.0 (5.0) | 6.2 (6.0) | 8.5 (7.3) | 7.3 (6.6) | 4.8 (4.3) | 7.0 (6.0) | 9.2 (7.8) | 8.0 (8.0) |
| Alcohol (ever) | 85.9% (1470011) | 86.5% (967590) | 84.8% (493100) | 82.9% (4438) | 84.4% (636) | 88.1% (111) | 82.8% (3187) | 83.5% (137) | 82.1% (812) |
| Smoking (ever) | 51.1% (874030) | 47.1% (526495) | 58.7% (341130) | 55.2% (2953) | 58.1% (438) | 59.5% (75) | 60.3% (2323) | 52.4% (86) | 53.6% (530) |
| BMI | 27.0 (5.3) | 26.7 (5.2) | 27.7 (5.2) | 26.8 (5.8) | 28.0 (5.7) | 28.2 (4.8) | 28.9 (5.2) | 26.5 (5.0) | 26.8 (5.5) |
| PAD | 6.7% (115013) | 0.0% (0) | 19.1% (110948) | 56.1% (3003) | 19.5% (147) | 12.7% (16) | 12.3% (474) | 44.5% (73) | 35.6% (352) |
| Hypertension | 15.9% (272152) | 11.6% (129653) | 24.2% (140459) | 12.5% (667) | 22.8% (172) | 25.4% (32) | 25.5% (981) | 21.3% (35) | 15.5% (153) |
| Stopped | 2.0% (34376) | 0.0% (0) | 5.3% (30745) | 10.3% (552) | 49.1% (370) | 59.5% (75) | 56.8% (2187) | 32.3% (53) | 39.8% (394) |
| Added | 1.6% (27275) | 0.0% (0) | 4.4% (25836) | 3.5% (189) | 19.0% (143) | 3.2% (4) | 21.7% (836) | 3.7% (6) | 26.4% (261) |
| Switched | 0.9% (14843) | 0.0% (0) | 2.1% (11930) | 11.3% (604) | 34.7% (262) | 65.1% (82) | 44.1% (1698) | 45.7% (75) | 19.4% (192) |
| Other drug within 5yrs | 0.7% (12626) | 0.4% (4237) | 1.4% (8242) | 0.9% (46) | 0.8% (6) | 0.8% (1) | 1.9% (74) | 6.1% (10) | 1.0% (10) |